Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1497253 · FYE Mar 31 · Prices AT CLOSE 2026-08-28 (USD) Last $0.29 · Day −2.63% · Mkt cap $4M · 1Y −84.7% · Off 52W high −94.6% · Vol (1Y) 138.2% Price2025-04-24 → 2026-08-28 VIVS close: $1.87 on 2025-04-24 to $0.29 on 2026-08-28. Split-adj closes · 240 of 329 · price returnⓘ At a glance | Short interest5.1% of sh out | | Days to cover1.0d | | 13F net flow (QoQ)+0.13% | | Top-10 13F concentration99.4% | | Next report (est.)2026-11-10 |
SI 2026-08-14 · 13F 2026-Q1ⓘ Key fundamentalsFY 2026 | Sales (TTM)$112,000 | | Earnings (TTM)-$12.3M | | ROE−35.3% | | Net margin−1727.8% | | Sales growth 3Y−54.2% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−84.2% | | 1Y−84.7% | | Since incept. (ann.)−75.3% |
Total return · from 2025-04-24ⓘ Risk | Ann. volatility (1Y)138.2% | | Ann. volatility (3Y)125.4% | | Sharpe (1Y)−0.78 | | Sharpe (3Y)−0.58 | | Max drawdown (1Y)−94.2% | | Max drawdown (3Y)−94.2% | | Beta (3Y vs SPY)2.52 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| GEODE CAPITAL MANAGEMENT, LLC | 36,850 | $52,697 | 1.41% | +78.5% | | GOLDMAN SACHS GROUP INC | 16,072 | $22,983 | 0.62% | new | | VANGUARD CAPITAL MANAGEMENT LLC | 15,371 | $21,981 | 0.59% | new | | BlackRock, Inc. | 11,817 | $16,898 | 0.45% | +0.0% | | VANGUARD FIDUCIARY TRUST CO | 7,003 | $10,014 | 0.27% | new | | CITIGROUP INC | 6,504 | $9,301 | 0.25% | +33.4% | | Tower Research Capital LLC (TRC) | 2,308 | $3,300 | 0.09% | +22.2% | | UBS Group AG | 952 | $1,361 | 0.04% | +5850.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-06 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-06 | −$0.25 | — | $18,000 | −51.4% | | 2026-03-31 | 2026-07-14 | −$2.20 | −144.0% | $40,000 | −21.6% | | 2025-12-31 | 2026-02-11 | −$1.03 | — | $26,000 | +8.3% | | 2025-09-30 | 2025-11-06 | −$0.98 | — | $28,000 | −6.7% |
As-reported XBRL · next 2026-11-10 est.ⓘ Segment mixFY2026 (ended Mar 2026) Royalty 100% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
